WCG Launches Neurostatus-eEDSS System
System incorporates Neurostatus Definitions booklet into the electronic data entry process to improve rater accuracy and consistency.
WCG has launched an enhanced digital version of the Neurostatus-Expanded Disability Status Scale (EDSS) to capture clinical trial data. Collaborating with Neurostatus-UHB Ltd., a University Hospital Basel (UHB) subsidiary led by CEO Marcus D'Souza, M.D. and Chief Operating Officer Evy Fricker, the e-EDSS aims to improve data quality for an MS clinical trial endpoint.
While this new system is designed to enhance the rater's data entry experience, it was built to provide better data quality through the implementation of the Neurostatus proprietary scoring algorithms and edit checks, supporting the rater with real-time feedback on data inconsistencies. A web-based data review process has been incorporated into the new e-EDSS system to facilitate faster review and oversight of data quality.
D'Souza said in a press release, "Data entry is extremely fast and easy, given its almost identical replication of the paper form with which researchers are already very familiar. This system also uniquely incorporates the Neurostatus Definitions booklet into the electronic data entry process, and we cannot wait to quantify the direct impact this has on rater accuracy and consistency."
Reference: WCG Collaborates With Leading Multiple Sclerosis KOL to Launch Neurostatus-eEDSS System/PRNewswire
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
